《高盛認股證牛熊證》 藥明低開高走 資金部署好倉 留意高槓桿購24829、中期購26102
正股表現:醫藥股昨日逆市下跌,當中藥明生物(2269)曾跌近5%及後觸底反彈,今早則下試117.2元後再度獲支持。現報121.4元。進而觀察藥明表現,可見近期股價在110至125元的區間上落,現時則於頂部整固。
資金流向:觀察個股輪證資金流向,可見昨日資金趁低部署好倉,當中認購證於昨日獲資金轉向流入,有約70萬元。牛證則錄得約850萬元資金流入,並集中在100元收回區域的遠牛。
產品選擇:投資者如看好,認購證方面的高槓桿選擇可留意屬行使價120至135元、2個月期以上的貼價條款中,槓桿最高的藥明購24829。中期選擇可留意低街貨藥明購26102。
藥明購24829,行使價130.88元,2021年11月25日到期,實際槓桿6.5倍,行使價120至135元、2個月期以上的貼價條款中,槓桿最高
藥明購26102,行使價138元,2022年01月21日到期,實際槓桿5.0倍,中期、低街貨
牛證方面,近牛選擇可留意藥明牛67083,與現價有約11元收回距離。遠牛選擇可留意藥明牛66248,與現價有約26元收回距離。
藥明牛67083,收回價110元,行使價108.5元,換股比率100,槓桿比率9.9倍,相近收回價近牛中街貨較低
藥明牛66248,收回價95元,行使價93.5元,換股比率100,槓桿比率4.4倍,相近收回價遠牛中街貨較低
註: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.